SCHEMBL29265249

SCHEMBL29265249

C=Cc1nn(CCCCCNC(=O)OC(C)(C)C)cc1[N+](=O)[O-]

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 2/20 0.42
▸ TDP1 Q9NUW8 1/20 0.41
▸ DRD2 P14416 7/20 0.39
▸ CA12 O43570 3/20 0.38
▸ CA1 P00915 3/20 0.38
▸ CA2 P00918 3/20 0.38
▸ CA9 Q16790 3/20 0.38
▸ MAOA P21397 1/20 0.37
▸ MAOB P27338 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.36
▸ ADORA3 P0DMS8 1/20 0.36
▸ ADORA2A P29274 1/20 0.36
▸ ADORA2B P29275 1/20 0.36
▸ ADORA1 P30542 1/20 0.36
▸ PIM1 P11309 1/20 0.36
▸ PIM3 Q86V86 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29265376 0.85 TDP1 (0.43) BRD4TDP1DRD2CA12CA1
SCHEMBL25405883 0.84 BRD4 (0.43) BRD4TDP1DRD2CA12CA1
SCHEMBL29265250 0.84 DRD2 (0.44) BRD4TDP1DRD2CA12CA1
SCHEMBL29265248 0.84 DRD2 (0.44) BRD4TDP1DRD2CA12CA1
SCHEMBL30380364 0.84 DRD2 (0.44) BRD4TDP1DRD2CA12CA1
SCHEMBL31376155 0.82 DRD2 (0.43) BRD4TDP1DRD2CA12CA1
SCHEMBL29265374 0.79 DRD2 (0.42) BRD4TDP1DRD2CA12CA1
SCHEMBL29265242 0.76 ALDH1A1 (0.47) BRD4TDP1DRD2CA12CA1
SCHEMBL30380512 0.74 DRD2 (0.51) DRD2
SCHEMBL25407920 0.73 TDP1 (0.45) BRD4TDP1DRD2CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240342318-A1 CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR PROTEINS RAYZEBIO, INC. 2024-10-17 — — US disclosed
EP-4380937-A1 CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR PROTEINS Rayzebio, Inc. (US) 2024-06-12 — — EP disclosed
CN-118176194-A Conjugates comprising covalent binding agents for targeting intracellular proteins 瑞择生物公司 2024-06-11 — — CN disclosed
WO-2023014988-A1 CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR PROTEINS RAYZEBIO, INC. (US) 2023-02-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240342318-A1 CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR PROTEINS CD2BP2, TP53, CAB39 BRD4 1450/4885TDP1 2872/4885DRD2 4562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback